Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis.
To clarify how intravenous immunoglobulin (IVIg) acts on Guillain-Barré syndrome, we investigated the effects of intact-type IVIg treatment on experimental allergic neuritis (EAN) induced by immunizing with synthetic peptide from bovine P2 protein. Treatment with intact-type IVIg (400 mg/kg/day) on days 0, 7, 14, 15 and 16 after immunization prevented the paralysis, whereas treatment with F(ab')2 failed to alter the clinical course. Intact-type IVIg treatment given on days 0 and 1 showed almost the same efficacy. These results suggest that intact-type IVIg is superior to F(ab')2 in ameliorating the clinical course of EAN and that the Fc portion might affect the immune system.
Miyagi
F
F
Pharmacological Research Department, Teijin Institute for Bio-Medical Research, Teijin Limited, Tokyo, Japan. jyg31172@token1.teijin.co.jp
Horiuchi
H
H
Nagata
I
I
Kitahara
S
S
Kiyoki
M
M
Komoriya
K
K
Yuki
N
N
D000818:Animals; D000906:Antibodies / Q000032:analysis; D002417:Cattle; D007114:Immunization; D007141:Immunoglobulin Fc Fragments / Q000276:immunology / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D018996:Myelin P2 Protein / Q000276:immunology; D009444:Neuritis, Autoimmune, Experimental / Q000276:immunology / Q000628:therapy*; D010446:Peptide Fragments / Q000276:immunology; D051381:Rats; D011917:Rats, Inbred Lew
D000906:Antibodies; D007141:Immunoglobulin Fc Fragments; D016756:Immunoglobulins, Intravenous; D018996:Myelin P2 Protein; D010446:Peptide Fragments